EP3230438C0 - N-glycosylation - Google Patents

N-glycosylation

Info

Publication number
EP3230438C0
EP3230438C0 EP15822904.7A EP15822904A EP3230438C0 EP 3230438 C0 EP3230438 C0 EP 3230438C0 EP 15822904 A EP15822904 A EP 15822904A EP 3230438 C0 EP3230438 C0 EP 3230438C0
Authority
EP
European Patent Office
Prior art keywords
glycolisation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
EP15822904.7A
Other languages
German (de)
English (en)
Other versions
EP3230438A2 (fr
EP3230438B1 (fr
Inventor
Henrik Clausen
Zhang Yang
Adnan Fevzi Halim
Eric Bennett
Carsten Behrens
Malene Bech Vester-Christensen
Shamim Herbert Rahman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Københavns Universitet
Danmarks Tekniske Universitet
Original Assignee
Københavns Universitet
Danmarks Tekniske Universitet
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Københavns Universitet, Danmarks Tekniske Universitet filed Critical Københavns Universitet
Priority to EP24217236.9A priority Critical patent/EP4502167A3/fr
Publication of EP3230438A2 publication Critical patent/EP3230438A2/fr
Application granted granted Critical
Publication of EP3230438B1 publication Critical patent/EP3230438B1/fr
Publication of EP3230438C0 publication Critical patent/EP3230438C0/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/505—Erythropoietin [EPO]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/005—Glycopeptides, glycoproteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/24—Interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/70—Enzymes
    • C12N2501/72—Transferases [EC 2.]
    • C12N2501/724—Glycosyltransferases (EC 2.4.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2511/00—Cells for large scale production

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
EP15822904.7A 2014-12-12 2015-12-11 N-glycosylation Active EP3230438B1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP24217236.9A EP4502167A3 (fr) 2014-12-12 2015-12-11 N-glycosylation

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462091056P 2014-12-12 2014-12-12
US201562193403P 2015-07-16 2015-07-16
PCT/DK2015/050391 WO2016091268A2 (fr) 2014-12-12 2015-12-11 N-glycosylation

Related Child Applications (1)

Application Number Title Priority Date Filing Date
EP24217236.9A Division EP4502167A3 (fr) 2014-12-12 2015-12-11 N-glycosylation

Publications (3)

Publication Number Publication Date
EP3230438A2 EP3230438A2 (fr) 2017-10-18
EP3230438B1 EP3230438B1 (fr) 2024-12-04
EP3230438C0 true EP3230438C0 (fr) 2024-12-04

Family

ID=55079928

Family Applications (2)

Application Number Title Priority Date Filing Date
EP24217236.9A Pending EP4502167A3 (fr) 2014-12-12 2015-12-11 N-glycosylation
EP15822904.7A Active EP3230438B1 (fr) 2014-12-12 2015-12-11 N-glycosylation

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP24217236.9A Pending EP4502167A3 (fr) 2014-12-12 2015-12-11 N-glycosylation

Country Status (4)

Country Link
US (4) US10858671B2 (fr)
EP (2) EP4502167A3 (fr)
ES (1) ES3003873T3 (fr)
WO (1) WO2016091268A2 (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10889845B2 (en) 2015-07-16 2021-01-12 University Of Copenhagen Production of N-glycoproteins for enzyme assisted glycomodification
AU2016369595B2 (en) 2015-12-18 2022-11-24 Tega Therapeutics, Inc. Cellular glycosaminoglycan compositions and methods of making and using
US20190330601A1 (en) * 2016-05-13 2019-10-31 University Of Copenhagen A cell-based array platform
ES2982085T3 (es) * 2016-06-20 2024-10-14 Octapharma Ag Medios y métodos para modificar alelos múltiples
US20200038430A1 (en) * 2016-12-16 2020-02-06 Tega Therapeutics, Inc. In vitro heparin and heparan sulfate compositions and methods of making and using
WO2019105770A1 (fr) 2017-11-28 2019-06-06 Danmarks Tekniske Universitet Glycosylation de protéines
EP3810761A1 (fr) * 2018-06-20 2021-04-28 Massachusetts Institute of Technology Procédés de glycoingénierie de protéoglycanes avec des structures glycanniques distinctes
IL280198B1 (en) * 2018-07-18 2025-09-01 Regenxbio Inc Treatment of mucopolysaccharidosis I with fully glycosylated human iduronidase-alpha-L (idus)
WO2020047282A1 (fr) 2018-08-29 2020-03-05 University Of Copenhagen Enzymes lysosomales modifiées par glyco-ingénierie basée sur les cellules
EP4087921A1 (fr) * 2020-01-07 2022-11-16 Limmatech Biologics AG Glyco-ingénierie à l'aide de cellules de leishmania
EP3954778B1 (fr) 2020-08-10 2023-10-04 Inbiose N.V. Production d'un mélange d'oligosaccharides non fucosylés neutres par une cellule
CN116096912A (zh) 2020-08-10 2023-05-09 因比奥斯公司 借由细胞生产中性未岩藻糖化寡糖的混合物
US20240100154A1 (en) * 2021-01-29 2024-03-28 University Of Maryland, College Park Compositions and methods for producing glyco-modified viral antigens
US20240263161A1 (en) 2021-06-04 2024-08-08 University Of Copenhagen Peptides with mucin-binding properties
WO2023044365A1 (fr) * 2021-09-17 2023-03-23 Doublerainbow Biosciences Inc. Utilisation de cyclodextrine pour améliorer la solubilité de substrats et augmenter l'efficacité de réaction de glycosylation enzymatique
CN115058418A (zh) * 2022-01-06 2022-09-16 扬州大学 一种Sec1基因敲除小鼠模型的sgRNA、构建方法及其应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2270147T4 (da) 1999-04-09 2020-08-31 Kyowa Kirin Co Ltd Fremgangsmåde til at kontrollere aktiviteten af immunologisk funktionelt molekyle
ES2556338T3 (es) 2001-10-10 2016-01-15 Novo Nordisk A/S Remodelación y glicoconjugación de péptidos
US20090311247A1 (en) * 2005-01-25 2009-12-17 Apollo Life Sciences Limited Molecules and chimeric molecules thereof
EP2527435B2 (fr) * 2007-07-12 2021-10-13 Sangamo BioSciences, Inc. Procédés et compositions pour inactiver l'expression génique d'alpha-1,6-fucosyltransférase (FUT 8)
WO2009075883A2 (fr) * 2007-12-12 2009-06-18 University Of Georgia Research Foundation, Inc. Biomarqueur de cancer de glycoprotéine
WO2011109600A1 (fr) * 2010-03-05 2011-09-09 Alnylam Pharmaceuticals, Inc. Compositions et procédés pour modifier le motif de glycosylation d'un polypeptide
US20130243744A1 (en) * 2011-01-06 2013-09-19 Michael J. Betenbaugh Method of production of recombinant glycoproteins with increased circulatory half-life in mammalian cells
JP2014520533A (ja) 2011-06-30 2014-08-25 シグマ−アルドリッチ・カンパニー・リミテッド・ライアビリティ・カンパニー Ｃｍｐ−ｎ−アセチルノイラミン酸ヒドロキシラーゼおよび／または糖タンパク質アルファ−１，３−ガラクトシルトランスフェラーゼを欠損する細胞
WO2013013013A2 (fr) * 2011-07-21 2013-01-24 Alnylam Pharmaceuticals, Inc. Compositions et procédés de production de glycoprotéines modifiées
US9464137B2 (en) * 2011-12-13 2016-10-11 Glykos Finland Oy Glycoprotein
BR112014016614B1 (pt) 2012-01-11 2022-02-01 Sigma-Aldrich Co. Llc Métodos para produzir uma célula deficiente em manosil (alfa-1,3-)-glicoproteína beta-1,2- nacetilglucosa-miniltransferase i (mgat1) e produzir uma proteína recombinante apresentando um ou mais resíduos de manose terminal
SG11201607038TA (en) * 2014-03-04 2016-09-29 Sigma Aldrich Co Llc Viral resistant cells and uses thereof

Also Published As

Publication number Publication date
EP3230438A2 (fr) 2017-10-18
EP3230438B1 (fr) 2024-12-04
US10858671B2 (en) 2020-12-08
US20210095317A1 (en) 2021-04-01
US20170369905A1 (en) 2017-12-28
EP4502167A2 (fr) 2025-02-05
ES3003873T3 (en) 2025-03-11
US20210102223A1 (en) 2021-04-08
US20210087587A1 (en) 2021-03-25
EP4502167A3 (fr) 2025-06-11
WO2016091268A2 (fr) 2016-06-16
WO2016091268A3 (fr) 2016-09-09

Similar Documents

Publication Publication Date Title
DK3183051T3 (da) Væske-til-luftmembranenergivekslere
DK3134402T3 (da) 4-amino-imidazoquinolinforbindelser
DK3006072T3 (da) Karadgang
DK3211743T3 (da) Ø-til-netværk-omskiftningsfremgangsmåde
DK3222714T3 (da) Phytasemutanter
DK3119396T3 (da) Muscarinreceptoragonister
EP3230438C0 (fr) N-glycosylation
DK3183340T3 (da) Termolabile exonukleaser
EP4011484C0 (fr) Anhydrase carbonique de thermovibrio ammonificans
DE112015001664A5 (de) Betätigungsaktuator
DE112015005041A5 (de) Gargerätevorrichtung
DK3154703T3 (da) Fuldkappe-snekkecentrifuge
DK3110439T3 (da) Pcsk9-vacciner
DE102014000623A8 (de) Halbhohlnietelement
DK3009858T3 (da) Skyradar
DE112015001633A5 (de) Betätigungsaktuator
DK3447493T3 (da) Proteinrettede ortologer
ES1133830Y (es) Columbario
DE202014005655U8 (de) llluminationsvorrichtung
DE112015005055A5 (de) Gargerätevorrichtung
DK3091875T3 (da) Vipbar taburet
DK3191825T3 (da) Kreatininbiosensor
FI10894U1 (fi) Putkieristyskouru
ES1137381Y (es) Trompo
ES1136185Y (es) Huevera

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20170706

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: UNIVERSITY OF COPENHAGEN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

PUAG Search results despatched under rule 164(2) epc together with communication from examining division

Free format text: ORIGINAL CODE: 0009017

17Q First examination report despatched

Effective date: 20191112

RIC1 Information provided on ipc code assigned before grant

Ipc: C12N 5/07 20100101AFI20191107BHEP

Ipc: C12N 15/87 20060101ALI20191107BHEP

Ipc: C12P 21/00 20060101ALI20191107BHEP

B565 Issuance of search results under rule 164(2) epc

Effective date: 20191112

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: DANMARKS TEKNISKE UNIVERSITET

Owner name: UNIVERSITY OF COPENHAGEN

INTG Intention to grant announced

Effective date: 20240402

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602015090573

Country of ref document: DE

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20241212

Year of fee payment: 10

U01 Request for unitary effect filed

Effective date: 20250103

U07 Unitary effect registered

Designated state(s): AT BE BG DE DK EE FI FR IT LT LU LV MT NL PT RO SE SI

Effective date: 20250115

U20 Renewal fee for the european patent with unitary effect paid

Year of fee payment: 10

Effective date: 20250121

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 3003873

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20250311

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20241204

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20250116

Year of fee payment: 10

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20250304

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20250305

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20250304

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20241204

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20241204

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20250404

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20241204

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20241204

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20241204

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20241231

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20241211

26N No opposition filed

Effective date: 20250905